citalopram has been researched along with Obsessive-Compulsive Disorder in 112 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several controlled trials have demonstrated the efficacy and safety of Fluoxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), but there is no controlled study on the effectiveness of Citalopram in this group." | 9.14 | A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). ( Alaghband-Rad, J; Hakimshooshtary, M, 2009) |
| "To assess the efficacy of quetiapine addition to citalopram in treatment-naive or medication-free obsessive-compulsive disorder (OCD) patients." | 9.14 | Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. ( Denys, D; Fluitman, SB; Meinardi, JC; Vulink, NC; Westenberg, HG, 2009) |
| "This study sought to investigate the efficacy of escitalopram at different dosages for the treatment of obsessive-compulsive disorder (OCD)." | 9.14 | Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. ( Deckersbach, T; Dougherty, DD; Jameson, M; Jenike, M; Keuthen, NJ; Loh, R; Thompson-Hollands, J, 2009) |
| "The aim of this study was to evaluate the efficacy and tolerability of high-dose escitalopram in patients suffering from obsessive-compulsive disorder (OCD)." | 9.13 | High-dose escitalopram for the treatment of obsessive-compulsive disorder. ( Barak, Y; Baruch, Y; Rabinowitz, I, 2008) |
| "Data from a multi-site randomized placebo-controlled study of citalopram in obsessive-compulsive disorder were analyzed." | 9.12 | Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. ( Andersen, EW; Overo, KF; Stein, DJ, 2007) |
| "A randomized, placebo controlled fixed-dose trial was undertaken to determine the efficacy and tolerability of escitalopram in obsessive-compulsive disorder (OCD), using paroxetine as the active reference." | 9.12 | Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. ( Andersen, EW; Fineberg, N; Stein, DJ; Tonnoir, B, 2007) |
| " citalopram administered with clomipramine, in treatment-resistant obsessive-compulsive disorder (OCD)." | 9.09 | Citalopram for treatment-resistant obsessive-compulsive disorder. ( Koran, LM; Paiva, RS; Pallanti, S; Quercioli, L, 1999) |
| "The adverse effects and potential clinical value of citalopram, a highly selective serotonin reuptake inhibitor, were examined in 23 children and adolescent (9-18 years old, 11 boys) with obsessive-compulsive disorder (OCD) in an open-label trial of citalopram 10-40 mg (modal 40 mg) daily." | 9.08 | Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. ( Thomsen, PH, 1997) |
| "This review focuses on the therapeutic use and the tolerability issues of escitalopram in the treatment of adult patients with panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and obsessive-compulsive disorder (OCD), on the basis of numerous recent short-term and long-term controlled studies in these disorders." | 8.84 | [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. ( Pelissolo, A, 2008) |
| "The present study aims to discuss the effect of escitalopram in glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) levels, and 5-Hydroxytryptamine (5-HT) in obsessive-compulsive disorder rats." | 7.96 | Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive-Compulsive Disorder Rats. ( Guo, HR; Huang, BL; Lv, PP; Ma, QG; Ren, YM; Wang, YL; Zhang, YY, 2020) |
| "This study explored the efficacy and tolerability of very high doses (maximum dose of >40 mg/day), high doses (maximum dose of 25-40 mg/day), and standard doses (maximum dose of ≤20 mg/day) of escitalopram (ESC) as an anti-obsessive-compulsive disorder treatment in a naturalistic clinical setting." | 7.77 | What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study. ( Hwang, JY; Jang, GE; Jang, JH; Kim, E; Kim, SN; Kwon, JS; Park, HY; Shim, G, 2011) |
| "To the authors' knowledge there is as of yet no study demonstrating in vivo alterations in human serotonin transporters (SERT) during clomipramine treatment in patients with obsessive-compulsive disorder." | 7.74 | Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. ( Aigner, M; Gutierrez-Lobos, K; Hornik, K; Pirker, W; Stompe, T; Thau, K; Wenzel, T; Zettinig, G; Zitterl, W; Zitterl-Eglseer, K, 2008) |
| "Serotonin and dopamine transporter (SERT, DAT) availabilities have prospectively been investigated using [123I]beta-CIT and single photon emission computed tomography in subjects with obsessive-compulsive disorder under treatment with the selective serotonin reuptake inhibitor citalopram." | 7.73 | SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). ( Hamann, C; Hegerl, U; Moeller, HJ; Mulert, C; Poepperl, G; Pogarell, O; Riedel, M; Sadowsky, N; Tatsch, K, 2005) |
| "Citalopram, a highly potent SSRI, is effective in the treatment of depressive disorders and obsessive-compulsive disorder (OCD); however, very few studies have reported concentration-effect relationships for SSRIs." | 7.72 | Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. ( Bareggi, SR; Bellodi, L; Bianchi, L; Cavallaro, R; Gervasoni, M; Siliprandi, F, 2004) |
| "This study aimed to evaluate the effect of citalopram in patients with refractory obsessive-compulsive disorder (OCD) which had not responded to previous antiobsessional treatments." | 7.71 | Citalopram in refractory obsessive-compulsive disorder: an open study. ( Cassano, GB; Ciapparelli, A; Dell'Osso, L; Gemignani, A; Marazziti, D; Nasso, ED; Pfanner, C; Presta, S, 2001) |
| "We report a severe case of obsessive-compulsive disorder (OCD) that responded to very high doses of citalopram (160 mg/day) after a poor response to clomipramine 250 mg/day for several years, alone or in combination with buspirone 30 mg/day or flupenthixol 4 mg/day." | 7.70 | Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder. ( Bejerot, S; Bodlund, O, 1998) |
| " Dosage adjustments were made within 2 weeks, depending on the tolerability of the patient." | 6.73 | Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. ( da Silva Prado, H; de Oliveira, IR; Galvão-de Almeida, A; Góis, CR; Leckman, JF; Miranda-Scippa, AM; Quarantini, LC; Rosário, MC; Santos-Jesus, R, 2007) |
| "Citalopram was well tolerated; only 4 to 6 patients in each dose group discontinued the study prematurely due to adverse events." | 6.70 | Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. ( Bang Hedegaard, K; Kasper, S; Lemming, OM; Montgomery, SA; Stein, DJ, 2001) |
| "Escitalopram was granted marketing authorization for the treatment of OCD from the European authorities in 2007 based on results from two Phase-III clinical trials in patients with moderate-to-severe OCD." | 6.44 | Escitalopram in the treatment of obsessive-compulsive disorder. ( Zohar, J, 2008) |
| "Its efficacy in treating depression was evident in both placebo-controlled and comparator trials." | 6.40 | Citalopram in the treatment of depression and other potential uses in psychiatry. ( Levin, GM; Tan, JY, 1999) |
| "Escitalopram was well tolerated, and the only detected side effects, nausea and headache, were mild and transient." | 5.40 | The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series. ( Bergman, J; Pashinian, A; Poyurovsky, M; Weizman, A, 2014) |
| "Citalopram treatment resulted in significant deactivation (p = 0." | 5.32 | Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. ( Carey, PD; Harvey, BH; Niehaus, DJ; Seedat, S; Stein, DJ; van der Linden, G; van Heerden, BB; Warwick, J, 2004) |
| "Several controlled trials have demonstrated the efficacy and safety of Fluoxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), but there is no controlled study on the effectiveness of Citalopram in this group." | 5.14 | A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). ( Alaghband-Rad, J; Hakimshooshtary, M, 2009) |
| "To assess the efficacy of quetiapine addition to citalopram in treatment-naive or medication-free obsessive-compulsive disorder (OCD) patients." | 5.14 | Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. ( Denys, D; Fluitman, SB; Meinardi, JC; Vulink, NC; Westenberg, HG, 2009) |
| "This study sought to investigate the efficacy of escitalopram at different dosages for the treatment of obsessive-compulsive disorder (OCD)." | 5.14 | Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. ( Deckersbach, T; Dougherty, DD; Jameson, M; Jenike, M; Keuthen, NJ; Loh, R; Thompson-Hollands, J, 2009) |
| "The aim of this study was to evaluate the efficacy and tolerability of high-dose escitalopram in patients suffering from obsessive-compulsive disorder (OCD)." | 5.13 | High-dose escitalopram for the treatment of obsessive-compulsive disorder. ( Barak, Y; Baruch, Y; Rabinowitz, I, 2008) |
| "The high percentage (between 40% and 60%) of resistance to first-line drugs, such as clomipramine or selective serotonin reuptake inhibitors, is a major problem in the pharmacologic management of obsessive-compulsive disorder (OCD)." | 5.13 | Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. ( Carlini, M; Catena Dell'osso, M; Consoli, G; Golia, F; Marazziti, D; Mungai, F; Pfanner, C; Presta, S, 2008) |
| "Data from a multi-site randomized placebo-controlled study of citalopram in obsessive-compulsive disorder were analyzed." | 5.12 | Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. ( Andersen, EW; Overo, KF; Stein, DJ, 2007) |
| "A randomized, placebo controlled fixed-dose trial was undertaken to determine the efficacy and tolerability of escitalopram in obsessive-compulsive disorder (OCD), using paroxetine as the active reference." | 5.12 | Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. ( Andersen, EW; Fineberg, N; Stein, DJ; Tonnoir, B, 2007) |
| " citalopram administered with clomipramine, in treatment-resistant obsessive-compulsive disorder (OCD)." | 5.09 | Citalopram for treatment-resistant obsessive-compulsive disorder. ( Koran, LM; Paiva, RS; Pallanti, S; Quercioli, L, 1999) |
| "The primary purpose of the study was to describe tolerability and effectiveness of citalopram in the treatment of adolescent obsessive-compulsive disorder (OCD)." | 5.09 | Long-term experience with citalopram in the treatment of adolescent OCD. ( Ebbesen, C; Persson, C; Thomsen, PH, 2001) |
| "The adverse effects and potential clinical value of citalopram, a highly selective serotonin reuptake inhibitor, were examined in 23 children and adolescent (9-18 years old, 11 boys) with obsessive-compulsive disorder (OCD) in an open-label trial of citalopram 10-40 mg (modal 40 mg) daily." | 5.08 | Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. ( Thomsen, PH, 1997) |
| "This review focuses on the therapeutic use and the tolerability issues of escitalopram in the treatment of adult patients with panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and obsessive-compulsive disorder (OCD), on the basis of numerous recent short-term and long-term controlled studies in these disorders." | 4.84 | [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. ( Pelissolo, A, 2008) |
| "The present study aims to discuss the effect of escitalopram in glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) levels, and 5-Hydroxytryptamine (5-HT) in obsessive-compulsive disorder rats." | 3.96 | Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive-Compulsive Disorder Rats. ( Guo, HR; Huang, BL; Lv, PP; Ma, QG; Ren, YM; Wang, YL; Zhang, YY, 2020) |
| "This study explored the efficacy and tolerability of very high doses (maximum dose of >40 mg/day), high doses (maximum dose of 25-40 mg/day), and standard doses (maximum dose of ≤20 mg/day) of escitalopram (ESC) as an anti-obsessive-compulsive disorder treatment in a naturalistic clinical setting." | 3.77 | What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study. ( Hwang, JY; Jang, GE; Jang, JH; Kim, E; Kim, SN; Kwon, JS; Park, HY; Shim, G, 2011) |
| "Data were analyzed from 2 prospective, double-blind, placebo-controlled trials of escitalopram in obsessive-compulsive disorder (OCD) to characterize the baseline levels of functional disability and impairment in health-related quality of life (HRQoL) and to assess the relationship between treatment outcomes (response or relapse) and disability or HRQoL." | 3.76 | Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. ( Fineberg, NA; Hollander, E; Legault, M; Marteau, F; Stein, DJ, 2010) |
| "To the authors' knowledge there is as of yet no study demonstrating in vivo alterations in human serotonin transporters (SERT) during clomipramine treatment in patients with obsessive-compulsive disorder." | 3.74 | Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. ( Aigner, M; Gutierrez-Lobos, K; Hornik, K; Pirker, W; Stompe, T; Thau, K; Wenzel, T; Zettinig, G; Zitterl, W; Zitterl-Eglseer, K, 2008) |
| "Serotonin and dopamine transporter (SERT, DAT) availabilities have prospectively been investigated using [123I]beta-CIT and single photon emission computed tomography in subjects with obsessive-compulsive disorder under treatment with the selective serotonin reuptake inhibitor citalopram." | 3.73 | SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). ( Hamann, C; Hegerl, U; Moeller, HJ; Mulert, C; Poepperl, G; Pogarell, O; Riedel, M; Sadowsky, N; Tatsch, K, 2005) |
| "Citalopram, a highly potent SSRI, is effective in the treatment of depressive disorders and obsessive-compulsive disorder (OCD); however, very few studies have reported concentration-effect relationships for SSRIs." | 3.72 | Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. ( Bareggi, SR; Bellodi, L; Bianchi, L; Cavallaro, R; Gervasoni, M; Siliprandi, F, 2004) |
| "This study aimed to evaluate the effect of citalopram in patients with refractory obsessive-compulsive disorder (OCD) which had not responded to previous antiobsessional treatments." | 3.71 | Citalopram in refractory obsessive-compulsive disorder: an open study. ( Cassano, GB; Ciapparelli, A; Dell'Osso, L; Gemignani, A; Marazziti, D; Nasso, ED; Pfanner, C; Presta, S, 2001) |
| "We report a severe case of obsessive-compulsive disorder (OCD) that responded to very high doses of citalopram (160 mg/day) after a poor response to clomipramine 250 mg/day for several years, alone or in combination with buspirone 30 mg/day or flupenthixol 4 mg/day." | 3.70 | Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder. ( Bejerot, S; Bodlund, O, 1998) |
| "A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant, clomipramine, was noted in a patient treated for major depression and obsessive-compulsive disorder." | 3.70 | Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. ( Bechtel, PR; Bizouard, P; Broly, F; Haffen, E; Sechter, D; Vandel, P; Vandel, S, 1999) |
| "Escitalopram has some unique features among selective serotonin reuptake inhibitors." | 2.87 | Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial. ( Dastgheib, SA; Modarresi, F; Mowla, A, 2018) |
| "Although obsessive-compulsive personality disorder (OCPD) is one of the most prevalent personality disorders, it is one of the least studied." | 2.82 | Efficacy and tolerability of pharmacotherapy for obsessive-compulsive personality disorder: a systematic review of randomized controlled trials. ( Gecaite-Stonciene, J; Hoffman, J; Lochner, C; Stein, DJ; Williams, T, 2022) |
| "Citalopram was associated with stronger prolactin response in the CN group (maximal percentage variation [max%Delta] = 65." | 2.73 | Acute hormonal changes after IV citalopram and treatment response in OCD. ( Bernik, M; Corregiari, FM; Gattaz, WF, 2007) |
| " Dosage adjustments were made within 2 weeks, depending on the tolerability of the patient." | 2.73 | Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. ( da Silva Prado, H; de Oliveira, IR; Galvão-de Almeida, A; Góis, CR; Leckman, JF; Miranda-Scippa, AM; Quarantini, LC; Rosário, MC; Santos-Jesus, R, 2007) |
| "Escitalopram was started at 10 mg/day, then increased and maintained at 20 mg/day for 10 weeks at the end of which completers were randomly assigned to placebo or escitalopram for 9 additional weeks." | 2.73 | Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. ( Allen, A; Baker, B; Chaplin, WF; Dell'Osso, B; Hadley, S; Hollander, E, 2008) |
| "Citalopram was well tolerated; only 4 to 6 patients in each dose group discontinued the study prematurely due to adverse events." | 2.70 | Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. ( Bang Hedegaard, K; Kasper, S; Lemming, OM; Montgomery, SA; Stein, DJ, 2001) |
| "The small number of studies that examined side effects within fixed-dose trials may have limited the power to examine the association between medication dosing and risk of headache." | 2.58 | Meta-analysis: Second generation antidepressants and headache. ( Bloch, MH; Olten, B; Telang, S; Walton, C, 2018) |
| "improves the core features of autism (social interaction, communication and behavioural problems);2." | 2.49 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Brignell, A; Hazell, P; Randall, M; Silove, N; Williams, K, 2013) |
| "improves the core features of autism (social interaction, communication and behavioural problems); 2." | 2.46 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Hazell, P; Silove, N; Wheeler, DM; Williams, K, 2010) |
| "Escitalopram was granted marketing authorization for the treatment of OCD from the European authorities in 2007 based on results from two Phase-III clinical trials in patients with moderate-to-severe OCD." | 2.44 | Escitalopram in the treatment of obsessive-compulsive disorder. ( Zohar, J, 2008) |
| "If clomipramine or citalopram have been used, an appropriate strategy consists in giving the same drug intravenously." | 2.41 | Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy. ( Albert, U; Bergesio, C; Bogetto, F; Maina, G; Pessina, E, 2002) |
| "Its efficacy in treating depression was evident in both placebo-controlled and comparator trials." | 2.40 | Citalopram in the treatment of depression and other potential uses in psychiatry. ( Levin, GM; Tan, JY, 1999) |
| "However, acute psychosis is not a commonly described manifestation of arsenic exposure." | 1.46 | An Unusual Case of Acute Psychosis With Obsessive-Compulsive Features Following Arsenic Poisoning. ( Abdel-Gawad, NM; Gharbaoui, Y; Pigott, TA; Teixeira, AL; Wu, HE, 2017) |
| "Escitalopram was well tolerated, and the only detected side effects, nausea and headache, were mild and transient." | 1.40 | The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series. ( Bergman, J; Pashinian, A; Poyurovsky, M; Weizman, A, 2014) |
| "Folie a deux (shared psychotic disorder) is often described in the context of schizophrenia." | 1.36 | Shared obsessive-compulsive disorder: broadening the concept of shared psychotic disorder. ( Greenberg, D; Jaworowski, S; Lerner, V; Mergui, J, 2010) |
| "Pica is a common disorder in childhood, however, in adults it is associated with mental retardation, psychosis and pregnancy." | 1.35 | Pica responding to SSRI: an OCD spectrum disorder? ( Bhatia, MS; Gupta, R, 2009) |
| "Measures related to PTSD and depression were obtained before, during, and after treatment." | 1.35 | Diagnosis and treatment of PTSD-related compulsive checking behaviors in veterans of the Iraq war: the influence of military context on the expression of PTSD symptoms. ( Foa, EB; Grubaugh, AL; Hamner, MB; Tuerk, PW, 2009) |
| "Hypersexuality in Alzheimer's disease (AD) has been rarely investigated." | 1.35 | Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. ( Bruno, G; Lenzi, GL; Talarico, G; Tosto, G, 2008) |
| "Citalopram treatment resulted in significant deactivation (p = 0." | 1.32 | Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. ( Carey, PD; Harvey, BH; Niehaus, DJ; Seedat, S; Stein, DJ; van der Linden, G; van Heerden, BB; Warwick, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (14.29) | 18.2507 |
| 2000's | 58 (51.79) | 29.6817 |
| 2010's | 33 (29.46) | 24.3611 |
| 2020's | 5 (4.46) | 2.80 |
| Authors | Studies |
|---|---|
| Gecaite-Stonciene, J | 1 |
| Williams, T | 1 |
| Lochner, C | 5 |
| Hoffman, J | 1 |
| Stein, DJ | 18 |
| van Staden, C | 1 |
| de Brouwer, G | 1 |
| Botha, TL | 1 |
| Finger-Baier, K | 1 |
| Brand, SJ | 1 |
| Wolmarans, D | 1 |
| Guo, HR | 1 |
| Huang, BL | 1 |
| Wang, YL | 1 |
| Zhang, YY | 1 |
| Ma, QG | 1 |
| Lv, PP | 1 |
| Ren, YM | 1 |
| Maneeton, N | 1 |
| Maneeton, B | 1 |
| Karawekpanyawong, N | 1 |
| Woottiluk, P | 1 |
| Putthisri, S | 1 |
| Srisurapanon, M | 1 |
| Chamberlain, SR | 3 |
| Kidd, M | 3 |
| Taljaard, L | 1 |
| Fineberg, NA | 4 |
| Robbins, TW | 1 |
| Wu, HE | 1 |
| Abdel-Gawad, NM | 1 |
| Gharbaoui, Y | 1 |
| Teixeira, AL | 1 |
| Pigott, TA | 1 |
| Faye, A | 1 |
| Kirpekar, V | 1 |
| Tadke, R | 1 |
| Gawande, S | 1 |
| Bhave, S | 1 |
| Mowla, A | 1 |
| Modarresi, F | 1 |
| Dastgheib, SA | 1 |
| Lee, J | 1 |
| Kim, BH | 2 |
| Kim, E | 3 |
| Howes, OD | 2 |
| Cho, KIK | 1 |
| Yoon, YB | 1 |
| Kwon, JS | 6 |
| Telang, S | 1 |
| Walton, C | 1 |
| Olten, B | 1 |
| Bloch, MH | 1 |
| van Bennekom, MJ | 1 |
| de Koning, PP | 1 |
| Denys, D | 4 |
| Müller-Vahl, KR | 1 |
| Szejko, N | 1 |
| Wilke, F | 1 |
| Jakubovski, E | 1 |
| Geworski, L | 1 |
| Bengel, F | 1 |
| Berding, G | 1 |
| Parmar, A | 1 |
| Sharan, P | 1 |
| Khandelwal, SK | 1 |
| Agarwal, K | 1 |
| Sharma, U | 1 |
| Jagannathan, NR | 1 |
| Rubin-Kahana, DS | 1 |
| Shelef, A | 1 |
| Weizman, A | 3 |
| Gothelf, D | 1 |
| Timinski, I | 1 |
| Spivak, B | 2 |
| Stryjer, R | 2 |
| Waltereit, R | 1 |
| Eifler, S | 1 |
| Schirmbeck, F | 1 |
| Zink, M | 1 |
| Williams, K | 2 |
| Brignell, A | 1 |
| Randall, M | 1 |
| Silove, N | 2 |
| Hazell, P | 2 |
| Wolmarans, de W | 2 |
| Brand, L | 1 |
| Harvey, BH | 5 |
| Hou, YC | 1 |
| Lai, CH | 1 |
| Bergman, J | 1 |
| Pashinian, A | 1 |
| Poyurovsky, M | 1 |
| Van Ameringen, M | 1 |
| Patterson, B | 1 |
| Park, JW | 1 |
| Kim, SN | 2 |
| Shin, SA | 1 |
| Turkheimer, FE | 1 |
| Lee, YS | 1 |
| Amerio, A | 1 |
| Tonna, M | 1 |
| Odone, A | 1 |
| Stubbs, B | 1 |
| Ghaemi, SN | 1 |
| Wolmarans, W | 1 |
| Bhikram, TP | 1 |
| Farb, NA | 1 |
| Ravindran, LN | 2 |
| Papadopoulos, YG | 1 |
| Conn, DK | 1 |
| Pollock, BG | 1 |
| Ravindran, AV | 2 |
| Hollander, E | 4 |
| Carey, PD | 2 |
| Seedat, S | 3 |
| Fineberg, N | 2 |
| Andersen, EW | 3 |
| Nissen, JB | 1 |
| Thomsen, PH | 3 |
| Jung, SM | 1 |
| Tosto, G | 1 |
| Talarico, G | 1 |
| Lenzi, GL | 1 |
| Bruno, G | 1 |
| Pelissolo, A | 1 |
| Marazziti, D | 2 |
| Golia, F | 1 |
| Consoli, G | 1 |
| Presta, S | 2 |
| Pfanner, C | 2 |
| Carlini, M | 1 |
| Mungai, F | 1 |
| Catena Dell'osso, M | 1 |
| Hezel, DM | 1 |
| Beattie, K | 1 |
| Stewart, SE | 1 |
| Alaghband-Rad, J | 1 |
| Hakimshooshtary, M | 1 |
| Figee, M | 1 |
| Vulink, NC | 2 |
| Fluitman, SB | 2 |
| Meinardi, JC | 1 |
| Westenberg, HG | 2 |
| Tuerk, PW | 1 |
| Grubaugh, AL | 1 |
| Hamner, MB | 1 |
| Foa, EB | 1 |
| Dougherty, DD | 2 |
| Jameson, M | 2 |
| Deckersbach, T | 2 |
| Loh, R | 2 |
| Thompson-Hollands, J | 1 |
| Jenike, M | 1 |
| Keuthen, NJ | 2 |
| Aggarwal, A | 1 |
| Jain, M | 1 |
| Garg, A | 1 |
| Jiloha, RC | 1 |
| Marteau, F | 1 |
| Legault, M | 1 |
| Krass, M | 1 |
| Rünkorg, K | 1 |
| Wegener, G | 1 |
| Volke, V | 1 |
| Wheeler, DM | 1 |
| Mergui, J | 1 |
| Jaworowski, S | 1 |
| Greenberg, D | 1 |
| Lerner, V | 1 |
| Shim, G | 1 |
| Park, HY | 2 |
| Jang, JH | 3 |
| Hwang, JY | 1 |
| Jang, GE | 1 |
| Simmons, C | 1 |
| van Honk, J | 1 |
| Ipser, J | 1 |
| Nazari, H | 1 |
| Momeni, N | 1 |
| Jariani, M | 1 |
| Tarrahi, MJ | 1 |
| van Nieuwerburgh, F | 1 |
| Deforce, D | 1 |
| Meinardi, JS | 1 |
| Corregiari, FM | 2 |
| Bernik, M | 2 |
| Cordeiro, Q | 1 |
| Vallada, H | 1 |
| Oulis, P | 1 |
| Dimitrakopoulos, S | 1 |
| Konstantakopoulos, G | 1 |
| Tsaltas, E | 1 |
| Kollias, K | 1 |
| Dambinsky, Y | 1 |
| Timinsky, I | 1 |
| Green, T | 1 |
| Kotler, M | 1 |
| Pallanti, S | 5 |
| Quercioli, L | 3 |
| Koran, LM | 2 |
| Takeuchi, H | 1 |
| Yatsugi, S | 1 |
| Yamaguchi, T | 1 |
| Woolley, JB | 1 |
| Heyman, I | 1 |
| Mukaddes, NM | 1 |
| Abali, O | 1 |
| Kaynak, N | 1 |
| Kordon, A | 1 |
| Broocks, A | 1 |
| Hohagen, F | 1 |
| Gabbay, V | 1 |
| Coffey, B | 1 |
| Ramacciotti, A | 1 |
| Pazzagli, A | 1 |
| Bareggi, SR | 1 |
| Bianchi, L | 2 |
| Cavallaro, R | 1 |
| Gervasoni, M | 1 |
| Siliprandi, F | 1 |
| Bellodi, L | 3 |
| Warwick, J | 1 |
| Niehaus, DJ | 1 |
| van der Linden, G | 1 |
| van Heerden, BB | 1 |
| Maina, G | 2 |
| Albert, U | 2 |
| Salvi, V | 1 |
| Bogetto, F | 2 |
| Bruscoli, M | 1 |
| Goodman, WK | 1 |
| Ozkara, C | 1 |
| Ozmen, M | 1 |
| Erdogan, A | 1 |
| Yalug, I | 1 |
| Sievers, M | 1 |
| Sato, T | 1 |
| Möller, HJ | 1 |
| Bottlender, R | 1 |
| Fontenelle, LF | 1 |
| Mendlowicz, MV | 1 |
| Miguel, EC | 1 |
| Versiani, M | 1 |
| Pogarell, O | 1 |
| Poepperl, G | 1 |
| Mulert, C | 1 |
| Hamann, C | 1 |
| Sadowsky, N | 1 |
| Riedel, M | 1 |
| Moeller, HJ | 1 |
| Hegerl, U | 1 |
| Tatsch, K | 1 |
| Stengler-Wenzke, K | 1 |
| Müller, U | 1 |
| Barthel, H | 1 |
| Angermeyer, MC | 1 |
| Sabri, O | 1 |
| Hesse, S | 1 |
| Jang, DP | 1 |
| Moon, WJ | 2 |
| Lee, JM | 2 |
| Ha, TH | 1 |
| Chung, EC | 2 |
| Kim, IY | 2 |
| Kim, SI | 2 |
| Habermeyer, B | 2 |
| Fuhr, P | 2 |
| Hiss, B | 1 |
| Alber, C | 1 |
| Müller-Spahn, F | 1 |
| Bailly, D | 1 |
| Tonnoir, B | 1 |
| Gattaz, WF | 1 |
| Walker, RH | 1 |
| Danek, A | 1 |
| Galvão-de Almeida, A | 1 |
| Quarantini, LC | 1 |
| Góis, CR | 1 |
| Santos-Jesus, R | 1 |
| Miranda-Scippa, AM | 1 |
| de Oliveira, IR | 1 |
| da Silva Prado, H | 1 |
| Leckman, JF | 1 |
| Rosário, MC | 1 |
| Yoo, SY | 1 |
| Shin, YW | 1 |
| Kim, DJ | 1 |
| Park, HJ | 1 |
| Wilhelm, S | 1 |
| Bhatia, MS | 1 |
| Gupta, R | 1 |
| Wickham, R | 1 |
| Varma, A | 1 |
| Tundo, A | 1 |
| Salvati, L | 1 |
| Busto, G | 1 |
| Di Spigno, D | 1 |
| Falcini, R | 1 |
| Rabinowitz, I | 1 |
| Baruch, Y | 1 |
| Barak, Y | 1 |
| Overo, KF | 1 |
| Shim, GS | 1 |
| Kang, DH | 1 |
| Sarkar, R | 1 |
| Klein, J | 1 |
| Krüger, S | 1 |
| Dell'Osso, B | 1 |
| Hadley, S | 1 |
| Allen, A | 1 |
| Baker, B | 1 |
| Chaplin, WF | 1 |
| Zohar, J | 1 |
| Zitterl, W | 1 |
| Aigner, M | 1 |
| Stompe, T | 1 |
| Zitterl-Eglseer, K | 1 |
| Gutierrez-Lobos, K | 1 |
| Wenzel, T | 1 |
| Zettinig, G | 1 |
| Hornik, K | 1 |
| Pirker, W | 1 |
| Thau, K | 1 |
| Berk, M | 1 |
| Koopowitz, LF | 1 |
| Szabo, CP | 1 |
| Maud, C | 1 |
| Bouwer, C | 1 |
| van Heerden, B | 1 |
| Mundo, E | 1 |
| Koponen, H | 1 |
| Lepola, U | 1 |
| Leinonen, E | 1 |
| Jokinen, R | 1 |
| Penttinen, J | 1 |
| Turtonen, J | 1 |
| Raitasuo, S | 1 |
| Virtanen, H | 1 |
| Raitasuo, J | 1 |
| Pidrman, V | 1 |
| Tůma, I | 1 |
| Mendelsohn, I | 1 |
| Potocnik, F | 1 |
| Van Kradenberg, J | 1 |
| Wessels, C | 1 |
| Bejerot, S | 1 |
| Bodlund, O | 1 |
| Tan, JY | 1 |
| Levin, GM | 1 |
| Pato, MT | 1 |
| Paiva, RS | 1 |
| Haffen, E | 1 |
| Vandel, P | 1 |
| Broly, F | 1 |
| Vandel, S | 1 |
| Sechter, D | 1 |
| Bizouard, P | 1 |
| Bechtel, PR | 1 |
| Montgomery, SA | 2 |
| Kasper, S | 2 |
| Bang Hedegaard, K | 1 |
| Lemming, OM | 1 |
| Wehr, AM | 1 |
| Namerow, LB | 1 |
| Dell'Osso, L | 1 |
| Gemignani, A | 1 |
| Ciapparelli, A | 1 |
| Nasso, ED | 1 |
| Cassano, GB | 1 |
| Ebbesen, C | 1 |
| Persson, C | 1 |
| Erzegovesi, S | 1 |
| Cavallini, MC | 1 |
| Cavedini, P | 1 |
| Diaferia, G | 1 |
| Locatelli, M | 1 |
| Tanghoj, P | 1 |
| Lamps, CA | 1 |
| Bergesio, C | 1 |
| Pessina, E | 1 |
| de Montigny, C | 1 |
| Blier, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD[NCT03993535] | Phase 4 | 250 participants (Actual) | Interventional | 2018-10-10 | Active, not recruiting | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)[NCT02410902] | Phase 3 | 190 participants (Actual) | Interventional | 2015-05-13 | Completed | ||
| An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin[NCT02649959] | Phase 3 | 405 participants (Anticipated) | Interventional | 2015-10-31 | Active, not recruiting | ||
| Bilateral Brain Stimulation in Trauma Therapy: a Randomized Clinical Trial[NCT03086083] | 40 participants (Actual) | Interventional | 2013-10-21 | Completed | |||
| A Multicenter Phase II Rater-Blinded Randomized Controlled Trial to Compare the Effectiveness of Eye Movement Desensitization Reprocessing Therapy vs. Treatment as Usual in Patients With Substance Use Disorder and History of Psychological Trauma[NCT03517592] | 142 participants (Anticipated) | Interventional | 2018-09-01 | Active, not recruiting | |||
| Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults[NCT00305500] | Phase 3 | 100 participants | Interventional | 2006-03-31 | Completed | ||
| Efficacy of Escitalopram in the Treatment of Internet Addiction[NCT00565422] | Phase 4 | 31 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564] | Phase 4 | 21 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
Primary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist (ABC) - Community sub scale for Irritability/Agitation (ABC-I) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-I is one of five discrete sub scales measured by the ABC. The scale range is 0-45. A higher score reflects higher severity of symptoms (irritability). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. The score was automatically calculated by the EDC. (NCT02410902)
Timeframe: Screening through Week 12/Termination
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -8.0 |
| Placebo | -5.5 |
Secondary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist- Community (ABC) sub scale for Lethargy / Social Withdrawal (ABC-L) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-L is one of five discrete sub scales measured by the ABC. The scale range is 0-48. A higher score reflects higher severity of symptoms (lethargy). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. (NCT02410902)
Timeframe: Screening through Week 12/Termination.
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -7.9 |
| Placebo | -6.6 |
14 reviews available for citalopram and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Efficacy and tolerability of pharmacotherapy for obsessive-compulsive personality disorder: a systematic review of randomized controlled trials.
Topics: Citalopram; Compulsive Personality Disorder; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Ran | 2022 |
Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis.
Topics: Adolescent; Child; Citalopram; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Prospective Studie | 2020 |
Meta-analysis: Second generation antidepressants and headache.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Citalopram; Depression; Double- | 2018 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Child Development Disorders, Pervasive; Citalopram; Fe | 2013 |
Intravenous anti-obsessive agents: a review.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Clomipramine; Drug Administration Sched | 2010 |
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Topics: Anxiety Disorders; Citalopram; Diagnosis, Differential; Humans; Obsessive-Compulsive Disorder; Panic | 2008 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.
Topics: Adrenergic Uptake Inhibitors; Citalopram; Clomipramine; Deep Brain Stimulation; Electric Stimulation | 2004 |
[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Case-Control Studies; Chil | 2006 |
Escitalopram in the treatment of obsessive-compulsive disorder.
Topics: Citalopram; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Humans; Obsessi | 2008 |
Citalopram in the treatment of depression and other potential uses in psychiatry.
Topics: Citalopram; Depression; Drug Interactions; Humans; Obsessive-Compulsive Disorder; Panic Disorder; Ra | 1999 |
Beyond depression: citalopram for obsessive-compulsive disorder.
Topics: Citalopram; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors | 1999 |
Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy.
Topics: Algorithms; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Dopam | 2002 |
32 trials available for citalopram and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
The effects of acute serotonin challenge on executive planning in patients with obsessive-compulsive disorder (OCD), their first-degree relatives, and healthy controls.
Topics: Adult; Attention; Citalopram; Cross-Over Studies; Double-Blind Method; Executive Function; Family; F | 2020 |
Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial.
Topics: Adult; Citalopram; Double-Blind Method; Female; Humans; Male; Obsessive-Compulsive Disorder; Outcome | 2018 |
Altered cognitive response to serotonin challenge as a candidate endophenotype for obsessive-compulsive disorder.
Topics: Adolescent; Adult; Citalopram; Cognition; Cross-Over Studies; Decision Making; Double-Blind Method; | 2016 |
The Effect of Intravenous Citalopram on the Neural Substrates of Obsessive-Compulsive Disorder.
Topics: Administration, Intravenous; Adolescent; Adult; Brain; Brain Mapping; Citalopram; Double-Blind Metho | 2016 |
Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Dose-Response Relationship, Drug; Doubl | 2008 |
Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
Topics: Adult; Citalopram; Clomipramine; Demography; Drug Resistance; Drug Synergism; Female; Humans; Male; | 2008 |
A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
Topics: Adolescent; Child; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind M | 2009 |
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Citalopram; Comorbidity; Diagnostic and Statistical Manual | 2009 |
Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Citalopram; Depression; Dose-Response Relationship, Drug; Female; Humans; Male; M | 2009 |
Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Child; Citalopram; Eye Movement Desensitization Reprocessing; Female; Humans; Mal | 2011 |
Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Child; Citalopram; Eye Movement Desensitization Reprocessing; Female; Humans; Mal | 2011 |
Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Child; Citalopram; Eye Movement Desensitization Reprocessing; Female; Humans; Mal | 2011 |
Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Child; Citalopram; Eye Movement Desensitization Reprocessing; Female; Humans; Mal | 2011 |
Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Catechol O-Methyltransferase; Citalopram; Dibenzothiazepines; Double-Bl | 2012 |
Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
Topics: Adult; Antipsychotic Agents; Anxiety; Citalopram; Compulsive Behavior; Diagnostic and Statistical Ma | 2013 |
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Topics: Adult; Citalopram; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 2002 |
Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Female; Humans; Male; Obsessive-Compulsive Dis | 2003 |
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies | 2004 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.
Topics: Adult; Brain; Brain Stem; Citalopram; Cocaine; Dose-Response Relationship, Drug; Down-Regulation; Dr | 2006 |
Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Double-Blind Method; Female; Humans; Ma | 2007 |
Acute hormonal changes after IV citalopram and treatment response in OCD.
Topics: Adult; Case-Control Studies; Citalopram; Female; Growth Hormone; Humans; Hydrocortisone; Infusions, | 2007 |
Obsessive-compulsive disorder: an open-label pilot trial of escitalopram.
Topics: Adult; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Obse | 2007 |
Open-label escitalopram treatment for pathological skin picking.
Topics: Adult; Anxiety; Citalopram; Comorbidity; Depression; Dose-Response Relationship, Drug; Female; Human | 2007 |
High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Data Interpretation, Statistical; Dose-R | 2008 |
Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
Topics: Adolescent; Adult; Aged; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessi | 2007 |
Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase.
Topics: Adult; Citalopram; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Administration | 2008 |
Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Female; Fluvoxamine; Humans; Male; Obse | 1997 |
Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
Topics: Adult; Citalopram; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Obsessive-Co | 1997 |
Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.
Topics: Adolescent; Child; Child, Preschool; Citalopram; Female; Humans; Male; Obsessive-Compulsive Disorder | 1997 |
Fenfluramine challenge test in obsessive-compulsive disorder--first results.
Topics: Adult; Citalopram; Clomipramine; Double-Blind Method; Female; Fenfluramine; Humans; Male; Obsessive- | 1997 |
Citalopram for treatment-resistant obsessive-compulsive disorder.
Topics: Adolescent; Adult; Citalopram; Clomipramine; Dose-Response Relationship, Drug; Double-Blind Method; | 1999 |
Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Citalopram; Disabled Persons; Dose-Response Rel | 2001 |
Long-term experience with citalopram in the treatment of adolescent OCD.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Citalopram; Cognitive Behavioral Therapy; Comb | 2001 |
Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Obsessi | 2001 |
66 other studies available for citalopram and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Dopaminergic and serotonergic modulation of social reward appraisal in zebrafish (Danio rerio) under circumstances of motivational conflict: Towards a screening test for anti-compulsive drug action.
Topics: Animals; Apomorphine; Behavior, Animal; Citalopram; Conflict, Psychological; Disease Models, Animal; | 2020 |
Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive-Compulsive Disorder Rats.
Topics: Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Citalopram; Glial Cell Line-Der | 2020 |
An Unusual Case of Acute Psychosis With Obsessive-Compulsive Features Following Arsenic Poisoning.
Topics: Adult; Antipsychotic Agents; Arsenic Poisoning; Citalopram; Humans; Male; Obsessive-Compulsive Disor | 2017 |
Obsession of pregnancy: Does it exist?
Topics: Attitude to Health; Citalopram; Clomipramine; Clonazepam; Cognitive Behavioral Therapy; Depressive D | 2017 |
Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
Topics: Adult; Age of Onset; Benzylamines; Brain; Brain Mapping; Carbon Radioisotopes; Case-Control Studies; | 2018 |
Social media and smartphone technology in the symptomatology of OCD.
Topics: Adult; Citalopram; Female; Humans; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; | 2018 |
Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder.
Topics: Adolescent; Adult; Citalopram; Female; Humans; Kinetics; Male; Obsessive-Compulsive Disorder; Protei | 2019 |
Brain neurochemistry in unmedicated obsessive-compulsive disorder patients and effects of 12-week escitalopram treatment:
Topics: Adolescent; Adult; Case-Control Studies; Caudate Nucleus; Choline; Citalopram; Female; Follow-Up Stu | 2019 |
The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder: an open-label study.
Topics: Adult; Antipsychotic Agents; Citalopram; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Dis | 2019 |
Visual and auditory hallucinations associated with citalopram treatment.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depressive D | 2013 |
Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
Topics: Animals; Brain; Citalopram; Disease Models, Animal; Obsessive-Compulsive Disorder; Peromyscus; Selec | 2013 |
Rapid responses of high-dose combined therapy of escitalopram and aripiprazole in a case of severe obsessive compulsive disorder with delusion.
Topics: Antipsychotic Agents; Aripiprazole; Citalopram; Delusions; Drug Therapy, Combination; Female; Humans | 2014 |
The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series.
Topics: Aged; Aged, 80 and over; Aging; Citalopram; Female; Hallucinations; Hearing Loss; Humans; Male; Musi | 2014 |
Topiramate augmentation in a patient with obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Citalopram; Drug Synergism; Fear; Female; Fructose; Hum | 2015 |
Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
Topics: Adult; Benzylamines; Brain; Carbon Radioisotopes; Case-Control Studies; Caudate Nucleus; Citalopram; | 2016 |
Treatment of comorbid bipolar disorder and anxiety disorders: A great challenge to modern psychiatry.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Citalopram; Comorbidity; Humans; Mal | 2016 |
Social behavior in deer mice as a novel interactive paradigm of relevance for obsessive-compulsive disorder (OCD).
Topics: Animals; Citalopram; Cohort Studies; Disease Models, Animal; Female; Male; Motor Activity; Obsessive | 2017 |
Excessive nest building is a unique behavioural phenotype in the deer mouse model of obsessive-compulsive disorder.
Topics: Animals; Citalopram; Disease Models, Animal; Nesting Behavior; Obsessive-Compulsive Disorder; Peromy | 2016 |
Differential treatment response, neuroinflammation, and psychosis associated with chromosome deletion.
Topics: Brain; Chromosome Deletion; Citalopram; Depressive Disorder; Humans; Inflammation Mediators; Obsessi | 2008 |
Clinicians' views on clinical examination and treatment of children and adolescents with obsessive-compulsive disorder (OCD). A Danish national survey study.
Topics: Adolescent; Child; Citalopram; Denmark; Female; Humans; Incidence; Male; Obsessive-Compulsive Disord | 2008 |
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Topics: Alzheimer Disease; Brain; Citalopram; Cognition Disorders; Disease Progression; Donepezil; Fluorodeo | 2008 |
Memantine as an augmenting agent for severe pediatric OCD.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Dopamine Agonists; | 2009 |
New pharmacotherapeutic approaches to obsessive-compulsive disorder.
Topics: Citalopram; Clinical Trials as Topic; Drug Evaluation; Humans; Obsessive-Compulsive Disorder; Predic | 2009 |
Diagnosis and treatment of PTSD-related compulsive checking behaviors in veterans of the Iraq war: the influence of military context on the expression of PTSD symptoms.
Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Humans; Iraq War, 2003-2011; Male; Military Personn | 2009 |
Carbamazepine for serotonin reuptake inhibitor nonresponder case of obsessive compulsive disorder.
Topics: Adult; Anticonvulsants; Carbamazepine; Citalopram; Depressive Disorder, Major; Humans; Male; Obsessi | 2009 |
Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Topics: Adaptation, Psychological; Adolescent; Adult; Aged; Citalopram; Cost of Illness; Diagnostic and Stat | 2010 |
Nitric oxide is involved in the regulation of marble-burying behavior.
Topics: Agmatine; Animals; Arginine; Behavior, Animal; Citalopram; Imidazoles; Indazoles; Male; Mice; Mice, | 2010 |
Shared obsessive-compulsive disorder: broadening the concept of shared psychotic disorder.
Topics: Citalopram; Clonazepam; Female; GABA Modulators; Humans; Male; Obsessive-Compulsive Disorder; Select | 2010 |
What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study.
Topics: Adult; Citalopram; Dose-Response Relationship, Drug; Female; Humans; Male; Obsessive-Compulsive Diso | 2011 |
Differential effects of escitalopram challenge on disgust processing in obsessive-compulsive disorder.
Topics: Adult; Citalopram; Double-Blind Method; Emotions; Facial Expression; Female; Humans; Male; Middle Ag | 2012 |
Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Citalopram; Endocrine System; Female; Genetic Markers | 2012 |
Low-dose aripiprazole in the treatment of SSRI-induced bruxism.
Topics: Antipsychotic Agents; Aripiprazole; Bruxism; Citalopram; Female; Humans; Middle Aged; Obsessive-Comp | 2012 |
Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Disease Models, Animal; Dose-Response | 2002 |
Dexamphetamine for obsessive-compulsive disorder.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
Obsessive-Compulsive disorder, Tourette's disorder, or pediatric autoimmune neuropsychiatric disorders associated with Streptococcus in an adolescent? Diagnostic and therapeutic challenges.
Topics: Adolescent; Antipsychotic Agents; Autoimmune Diseases; Citalopram; Clinical Laboratory Techniques; D | 2003 |
A setting including psychotherapy and psychopharmacological treatment in a case of anorexia nervosa with obsessive compulsive disorder comorbidity.
Topics: Adult; Anorexia Nervosa; Citalopram; Female; Humans; Obsessive-Compulsive Disorder; Psychotherapy; S | 1997 |
Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Citalopram; Female; Humans; Male; Middle Aged; Obsess | 2004 |
Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
Topics: Adult; Anxiety Disorders; Brain; Citalopram; Female; Humans; Limbic System; Male; Obsessive-Compulsi | 2004 |
Topiramate related obsessive-compulsive disorder.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Carbamazepine; Citalopram; Dose-Re | 2005 |
Obsessive-compulsive disorder (OCD) with psychotic symptoms and response to treatment with SSRI.
Topics: Adult; Behavior Therapy; Citalopram; Drug Administration Schedule; Female; Humans; Obsessive-Compuls | 2005 |
Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cita | 2005 |
SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD).
Topics: Brain; Citalopram; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; T | 2005 |
A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder.
Topics: Adult; Aspartic Acid; Brain; Brain Chemistry; Choline; Citalopram; Creatine; Female; Frontal Lobe; G | 2006 |
Obsessive-compulsive disorder due to neuroacanthocytosis treated with citalopram. A case report.
Topics: Adult; Chorea; Citalopram; Humans; Male; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake | 2006 |
Obsessive-compulsive disorders due to neuroacanthocytosis treated with citalopram.
Topics: Chorea; Citalopram; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibitors; | 2007 |
Obsessive-compulsive disorders due to neuroacanthocytosis treated with citalopram.
Topics: Adult; Amino Acid Transport Systems, Neutral; Chorea; Citalopram; Humans; Male; Obsessive-Compulsive | 2007 |
White matter abnormalities in drug-naïve patients with obsessive-compulsive disorder: a diffusion tensor study before and after citalopram treatment.
Topics: Adult; Anisotropy; Antidepressive Agents, Second-Generation; Brain; Caudate Nucleus; Cerebral Cortex | 2007 |
Pica responding to SSRI: an OCD spectrum disorder?
Topics: Adult; Anticonvulsants; Citalopram; Clonazepam; Drug Therapy, Combination; Female; Humans; Obsessive | 2009 |
Ziprasidone-associated mania in a case of obssessive-compulsive disorder.
Topics: Anticonvulsants; Bipolar Disorder; Citalopram; Clonazepam; Dose-Response Relationship, Drug; Drug In | 2007 |
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Topics: Adult; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexan | 2007 |
High-dose escitalopram treatment in patients with obsessive-compulsive disorder: a naturalistic case series.
Topics: Adolescent; Adult; Citalopram; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Ret | 2008 |
Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Citalopram; Drug Therapy, Combination; Female; | 2008 |
Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder.
Topics: Adult; Binding, Competitive; Citalopram; Clomipramine; Down-Regulation; Female; Humans; Hypothalamus | 2008 |
Antidepressant induced mania in obsessive compulsive disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Citalopram; Clomipramine; Female; Fluoxetine; Follow | 1996 |
Treatment of childhood obsessive-compulsive disorder with citalopram.
Topics: Antidepressive Agents; Child; Citalopram; Female; Humans; Obsessive-Compulsive Disorder; Selective S | 1996 |
Pica and the obsessive-compulsive spectrum disorders.
Topics: 1-Naphthylamine; Adolescent; Adult; Antidepressive Agents; Child; Citalopram; Clomipramine; Female; | 1996 |
Anorexia nervosa, major depression, and obsessive-compulsive disorder in a Down's syndrome patient.
Topics: Adult; Anorexia Nervosa; Antidepressive Agents; Citalopram; Depressive Disorder; Down Syndrome; Huma | 1998 |
Use of the selective serotonin reuptake inhibitor citalopram in a possible animal analogue of obsessive-compulsive disorder.
Topics: Animals; Citalopram; Dermatitis; Disease Models, Animal; Dogs; Female; Follow-Up Studies; Grooming; | 1998 |
Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 1998 |
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Clomipramine; Cytochrome | 1999 |
Inositol in the treatment of trichotillomania and compulsive skin picking.
Topics: Adult; Citalopram; Drug Therapy, Combination; Female; Humans; Inositol; Obsessive-Compulsive Disorde | 2001 |
Citalopram for OCD and Tourette's syndrome.
Topics: Child; Citalopram; Humans; Male; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibit | 2001 |
Citalopram in refractory obsessive-compulsive disorder: an open study.
Topics: Adolescent; Adult; Citalopram; Dose-Response Relationship, Drug; Drug Administration Schedule; Femal | 2001 |
Clinical predictors of drug response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Citalopram; Clomipramine; Drug Resistance; Female; Fl | 2001 |
Citalopram and psychotic symptoms.
Topics: Adolescent; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administr | 2002 |
Desensitization of terminal 5-HT autoreceptors by 5-HT reuptake blockers.
Topics: Animals; Citalopram; Clomipramine; Clorgyline; Humans; Monoamine Oxidase Inhibitors; Obsessive-Compu | 1991 |